Emergent BioSolutions (EBS) Assets (2010 - 2026)

Emergent BioSolutions' Assets history runs 17 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Assets fell 7.41% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 7.41% YoY), while the FY2025 annual figure was $1.3 billion, down 5.12% from the prior year.
• Assets was $1.3 billion for Q1 2026 at Emergent BioSolutions, roughly flat from $1.3 billion in the prior quarter.
• In the past five years, Assets ranged from a high of $3.2 billion in Q4 2022 to a low of $1.3 billion in Q4 2025.
• Historically, Assets has averaged $2.0 billion across 5 years, with a median of $1.8 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets advanced 7.05% in 2022, then slumped 42.42% in 2023.
• A 5-year view of Assets shows it stood at $3.2 billion in 2022, then plunged by 42.42% to $1.8 billion in 2023, then fell by 23.78% to $1.4 billion in 2024, then declined by 5.12% to $1.3 billion in 2025, then advanced by 0.14% to $1.3 billion in 2026.
• The last three Assets figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.